Abstract
Multiple sclerosis (MS) is a progressive inflammatory demyelinating disease in the central nervous system (CNS). Melatonin is an effective treatment in MS patients and experimental autoimmune encephalomyelitis (EAE), a mouse model of MS. Melatonin secretion peaks at 2 AM, concomitant with the time at which the muscles are resting and the body is exerting its antioxidant activity. The current study was designed to investigate combination treatment of baclofen, a muscle relaxant drug, and melatonin in EAE mice. Results showed that melatonin (Mel) alone or in combination with baclofen (Bac + Mel) reduced clinical scores and demyelination by significantly increasing myelin oligodendrocyte glycoprotein (MOG) levels, a marker for mature oligodendrocytes, compared to EAE mice. Moreover, Mel or Bac + Mel therapy caused a significant increase in IL-4 serum levels, an anti-inflammatory cytokine, whereas IFN-γ serum levels, a pro-inflammatory cytokine, were significantly reduced. On the other hand, Mel or Bac + Mel caused a significant reduction in malondialdehyde (MDA) levels, a marker of oxidative stress, in comparison to EAE mice. In contrast, the activity of antioxidant enzymes catalase (CAT) and superoxide dismutase (SOD) was significantly increased in Mel and Bac + Mel groups. In summary, combination therapy improved clinical scores and tend to enhance the efficiency of melatonin treatment by further promoting remyelination, decreasing inflammation, and stimulating the activity of antioxidant enzymes, which suggests that prior spasticity treatment increases the efficacy of melatonin therapy in EAE mouse model of MS. Further experimental and clinical studies are needed to ensure the beneficial role of this combination strategy.
References
Adamczyk-Sowa M, Pierzchala K, Sowa P, Mucha S, Sadowska-Bartosz I, Adamczyk J, Hartel M (2014) Melatonin acts as antioxidant and improves sleep in MS patients. Neurochem Res 39:1585–1593
Albright AL, Barron WB, Fasick MP, Polinko P, Janosky J (1993) Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 270:2475–2477
Alvarez-Sanchez N, Cruz-Chamorro I, Lopez-Gonzalez A, Utrilla JC, Fernandez-Santos JM, Martinez-Lopez A, Lardone PJ, Guerrero JM, Carrillo-Vico A (2015) Melatonin controls experimental autoimmune encephalomyelitis by altering the T effector/regulatory balance. Brain Behav Immun 50:101–114
Brown P (1994) Pathophysiology of spasticity. J Neurol Neurosurg Psychiatry 57:773–777
Chen SJ, Huang SH, Chen JW, Wang KC, Yang YR, Liu PF, Lin GJ, Sytwu HK (2016) melatonin enhances interleukin-10 expression and suppresses chemotaxis to inhibit inflammation in situ and reduce the severity of experimental autoimmune encephalomyelitis. Int Immunopharmacol 31:169–177
Constant SL, Bottomly K (1997) Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 15:297–322
Emamgholipour S, Hossein-Nezhad A, Sahraian MA, Askarisadr F, Ansari M (2016) Evidence for possible role of melatonin in reducing oxidative stress in multiple sclerosis through its effect on SIRT1 and antioxidant enzymes. Life Sci 145:34–41
Farez MF, Mascanfroni ID, Mendez-Huergo SP, Yeste A, Murugaiyan G, Garo LP, Balbuena Aguirre ME, Patel B, Ysrraelit MC, Zhu C, Kuchroo VK, Rabinovich GA, Quintana FJ, Correale J (2015) Melatonin contributes to the seasonality of multiple sclerosis relapses. Cell 162:1338–1352
Gelber DA, Jozefczyk PB (1999) The management of spasticity in multiple sclerosis. Int J MS Care 1:35–49
Ghareghani M, Dokoohaki S, Ghanbari A, Farhadi N, Zibara K, Khodadoust S, Parishani M, Ghavamizadeh M, Sadeghi H (2017a) Melatonin exacerbates acute experimental autoimmune encephalomyelitis by enhancing the serum levels of lactate: a potential biomarker of multiple sclerosis progression. Clin Exp Pharmacol Physiol 44:52–61
Ghareghani M, Sadeghi H, Zibara K, Danaei N, Azari H, Ghanbari A (2017b) Melatonin increases oligodendrocyte differentiation in cultured neural stem cells. Cell Mol Neurobiol 37:1319–1324
Ghareghani M, Zibara K, Sadeghi H, Dokoohaki S, Sadeghi H, Aryanpour R, Ghanbari A (2017c) Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis. Sci Rep 7:4923
Hagemeier K, Bruck W, Kuhlmann T (2012) Multiple sclerosis—remyelination failure as a cause of disease progression. Histol Histopathol 27:277–287
Hilliard A, Stott C, Wright S, Guy G, Pryce G, Al-Izki S, Bolton C, Giovannoni G (2012) Evaluation of the effects of Sativex (THC BDS: CBD BDS) on inhibition of spasticity in a chronic relapsing experimental allergic autoimmune encephalomyelitis: a model of multiple sclerosis. ISRN Neurol 2012:7
Jeong JS, Suh JK, Cho ES, Kim DW, Jeong MA (2013) Antioxidant effect of muscle relaxants (vecuronium, rocuronium) on the rabbit abdominal aortic endothelial damage induced by reactive oxygen species. Korean J Anesthesiol 65:552–558
Kang JC, Ahn M, Kim YS, Moon C, Lee Y, Wie MB, Lee YJ, Shin T (2001) Melatonin ameliorates autoimmune encephalomyelitis through suppression of intercellular adhesion molecule-1. J Vet Sci 2:85–89
Liu W, Li W-M, Gao C, Sun N-L (2005) Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. J Autoimmun 25:258–263
Malfitano AM, Proto MC, Bifulco M (2008) Cannabinoids in the management of spasticity associated with multiple sclerosis. Neuropsychiatr Dis Treat 4:847–853
Melamud L, Golan D, Luboshitzky R, Lavi I, Miller A (2012) Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis. J Neurol Sci 314:37–40
Middel B, Kuipers-Upmeijer H, Bouma J, Staal M, Oenema D, Postma T, Terpstra S, Stewart R (1997) Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry 63:204–209
Mirshafiey A, Mohsenzadegan M (2009) Antioxidant therapy in multiple sclerosis. Immunopharmacol Immunotoxicol 31:13–29
Nashold FE, Nelson CD, Brown LM, Hayes CE (2013) One calcitriol dose transiently increases Helios+ FoxP3+ T cells and ameliorates autoimmune demyelinating disease. J Neuroimmunol 263:64–74
Olivier P, Fontaine RH, Loron G, Van Steenwinckel J, Biran V, Massonneau V, Kaindl A, Dalous J, Charriaut-Marlangue C, Aigrot MS, Pansiot J, Verney C, Gressens P, Baud O (2009) Melatonin promotes oligodendroglial maturation of injured white matter in neonatal rats. PLoS One 4:e7128
Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B, Kroin JS (1989) Intrathecal baclofen for severe spinal spasticity. N Engl J Med 320:1517–1521
Powers SK, Jackson MJ (2008) Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. Physiol Rev 88:1243–1276
Reiter RJ (1993) The melatonin rhythm: both a clock and a calendar. Experientia 49:654–664
Reiter RJ, Melchiorri D, Sewerynek E, Poeggeler B, Barlow-Walden L, Chuang J, Ortiz GG, Acuna-Castroviejo D (1995) A review of the evidence supporting melatonin’s role as an antioxidant. J Pineal Res 18:1–11
Sandyk R (1993) Multiple sclerosis: the role of puberty and the pineal gland in its pathogenesis. Int J Neurosci 68:209–225
Sullivan-Gunn MJ, Lewandowski PA (2013) Elevated hydrogen peroxide and decreased catalase and glutathione peroxidase protection are associated with aging sarcopenia. BMC Geriatr 13:104
Wingerchuk DM, Lucchinetti CF, Noseworthy JH (2001) Multiple sclerosis: current pathophysiological concepts. Lab Invest 81:263–281
Acknowledgements
This work was supported by a grant from Cell and Molecular Research Center of Yasuj University of Medical Science, Yasuj, Iran.
Author information
Authors and Affiliations
Contributions
MG, KZ, and NF designed the study, collected data, and interpreted results. MG and KZ wrote the paper. HS participated in the collection and interpretation of some data.
Corresponding author
Ethics declarations
Conflict of interest
The authors have nothing to disclose.
Rights and permissions
About this article
Cite this article
Ghareghani, M., Zibara, K., Sadeghi, H. et al. Spasticity Treatment Ameliorates the Efficacy of Melatonin Therapy in Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model of Multiple Sclerosis. Cell Mol Neurobiol 38, 1145–1151 (2018). https://doi.org/10.1007/s10571-018-0580-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10571-018-0580-y